We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos and Prolysis Extend Research Collaboration
News

Galapagos and Prolysis Extend Research Collaboration

Galapagos and Prolysis Extend Research Collaboration
News

Galapagos and Prolysis Extend Research Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos and Prolysis Extend Research Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV and Prolysis Ltd have announced an extension of the research collaboration started earlier this year. BioFocus, the service division of Galapagos, is progressing a lead optimisation program for Prolysis to identify dual enzyme inhibitors that can overcome the problem of antibiotic resistance.

Under the terms of the collaboration, Prolysis will fund BioFocus research for medicinal chemistry work throughout 2006. Prolysis also has the option to access in vitro ADMET and computational chemistry services from BioFocus during that period.

"Progress made in the collaboration with Prolysis indicates how BioFocus' drug discovery services can accelerate a development program," said Onno van de Stolpe, Chief Executive Officer of Galapagos.

"We are pleased that Prolysis, a leader in anti-bacterial agent discovery and development, chooses BioFocus to move this key project through lead optimisation to development candidate nomination." 
 
Steve Ruston, Chief Executive Officer of Prolysis, added, "We have been very pleased with the quality of the collaboration with BioFocus to date and look forward to it making a substantial contribution to achieving our business objectives in the coming year."

Advertisement